Ocular Therapeutix (OCUL) Cash from Financing Activities (2013 - 2026)

Ocular Therapeutix's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $294000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 92.97% year-over-year to $294000.0; the TTM figure through Mar 2026 stood at $557.8 million (up 3601.61% YoY), while the FY2025 annual figure was $561.7 million, up 69.14% from the prior year.
• Cash from Financing Activities was $294000.0 for Q1 2026 at Ocular Therapeutix, down from $449.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $449.4 million in Q4 2025 to a low of $78000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $62.7 million across 5 years, with a median of $4.2 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 411724.36% in 2024, then sank 98.7% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $458000.0 in 2022, then jumped by 23517.9% to $108.2 million in 2023, then sank by 95.83% to $4.5 million in 2024, then soared by 9857.37% to $449.4 million in 2025, then slumped by 99.93% to $294000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $294000.0 (Q1 2026), $449.4 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.